Circulating Tumor DNA Monitoring in Breast Cancer Undergoing Neoadjuvant Therapy

In the prospective, open, observational study, we aim to evaluate whether circulating tumor DNA (ctDNA) can be the marker of the response to neoadjuvant therapy in stage I-III breast cancer.

Inclusion Criteria:Patient is ≥ 18 years-old at the time of consent to participate this trialPatients with stage I-III invasive breast cancerNo prior anti-cancer treatmentFelt to be a possible candidate for neoadjuvant therapy by their physicianExclusion Criteria:Known to have other aggressive malignant tumor in the past 5 years.Breast cancer during lactation; Inflammatory breast cancer; Acute inflammatory disease, pregnancy and other conditions may affect the levels of ctDNA and/or peripheral inflammatory indicators.There are other concomitant diseases that seriously threaten the patient's safety or affect the patient's completion of the study, such as serious infection, liver disease, cardiovascular disease, kidney disease, respiratory disease or uncontrolled diabetes or dyslipidemia.The investigator determines that subjects are not appropriate to participate in the study due to other factors.